HEM Hemosense

HemoSense, Inc. (AMEX:HEM) today announced that it has signed an agreement with Laboratory Corporation of America� Holdings (LabCorp�) (NYSE:LH) to supply the HemoSense portable INRatio� PT/INR monitoring system to identified LabCorp laboratories. The INRatio system will also be made available to selected LabCorp patient service centers and affiliated physician offices nationwide. HemoSense�s INRatio system consists of a small, portable meter and disposable test strips that provide a quick and accurate measurement of blood-clotting time, known as a PT/INR value. This test helps patients reduce the risk of strokes through frequent monitoring of anticoagulation therapy. �We are delighted to be working with a recognized laboratory leader, and this agreement with LabCorp is one more step toward our goal of increasing the HemoSense share of a growing market in patient blood coagulation monitoring,� said Timothy Still, executive VP and chief commercial officer of HemoSense. �Monitoring patients� PT/INR levels at the point-of-care can help improve the treatment, health and lifestyle of patients taking warfarin.� According to the U.S. Centers for Medicare & Medicaid Services (CMS), monthly blood coagulation testing is inadequate for the majority of patients on chronic warfarin therapy. HemoSense�s INRatio system reduces the time and inconvenience required to manage warfarin and allows patients to play an active role in management of their warfarin dosage, encouraging optimal patient compliance, more time spent within the patient�s therapeutic range and immediate dose management. The INRatio system is based on a reliable proprietary electrochemical technology that generates rapid PT/INR results simultaneously with two levels of quality control from a single drop of blood. Patient training is straightforward and test strips can be stored at room temperature for up to one year. Tests performed using the INRatio system in the point-of-care setting are currently reimbursed by Medicare and private payers for all patients on warfarin. The INRatio system is sold through a prestigious and growing network of distributors in the U.S. and internationally in 23 countries. About HemoSense HemoSense is a point-of-care diagnostic healthcare company that develops, manufactures and markets easy-to-use, handheld blood coagulation systems for monitoring patients taking warfarin. The HemoSense INRatio system, used by healthcare professionals and patients themselves, consists of a small monitor and disposable test strips. It provides accurate and convenient measurement of blood clotting time, or PT/INR values. Routine measurements of PT/INR are necessary for the safe and effective management of the patient's warfarin dosing. INRatio is sold in the United States and internationally. For more information, visit www.hemosense.com. About LabCorp� Laboratory Corporation of America� Holdings (LabCorp�), a S&P 500 company, is a pioneer in commercializing new diagnostic technologies and the first in its industry to embrace genomic testing. With annual revenues of $3.6 billion in 2006, over 25,000 employees nationwide, and more than 220,000 clients, LabCorp offers clinical assays ranging from routine blood analyses to HIV and genomic testing. LabCorp combines its expertise in innovative clinical testing technology with its Centers of Excellence: The Center for Molecular Biology and Pathology, in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; ViroMed Laboratories, Inc. based in Minneapolis, MN; The Center for Esoteric Testing in Burlington, NC; DIANON Systems, Inc. based in Stratford, CT; US LABS based in Irvine, CA; and Esoterix and its Colorado Coagulation, Endocrine Sciences, and Cytometry Associates laboratories. LabCorp clients include physicians, government agencies, managed care organizations, hospitals, clinical labs, and pharmaceutical companies. To learn more about LabCorp, visit www.LabCorp.com. HemoSense� and INRatio� are registered trademarks of HemoSense, Inc.